{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:00:30Z","timestamp":1784858430992,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL169954"],"award-info":[{"award-number":["R01HL169954"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71307-0","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:34:33Z","timestamp":1775327673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-1777","authenticated-orcid":false,"given":"Chungsoo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-2124","authenticated-orcid":false,"given":"Clair","family":"Blacketer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ostropolets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8274-0357","authenticated-orcid":false,"given":"Talita","family":"Duarte-Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Viernes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-1394","authenticated-orcid":false,"given":"Thomas","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-0220","authenticated-orcid":false,"given":"Andrea","family":"Pistillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5426-8657","authenticated-orcid":false,"given":"Mui","family":"Van Zandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Minty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-6399","authenticated-orcid":false,"given":"Seng Chan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Sawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6568-1781","authenticated-orcid":false,"given":"Shoko","family":"Sawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Young","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3197-2657","authenticated-orcid":false,"given":"Arya","family":"Aminorroaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5664-4126","authenticated-orcid":false,"given":"Lovedeep S.","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-8304","authenticated-orcid":false,"given":"Aline F.","family":"Pedroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Thangaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-1942","authenticated-orcid":false,"given":"Kenneth K. C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallis C. Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-6199","authenticated-orcid":false,"given":"Rohan","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-5361","authenticated-orcid":false,"given":"Martijn J.","family":"Schuemie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hripcsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-127X","authenticated-orcid":false,"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9818-479X","authenticated-orcid":false,"given":"Marc A.","family":"Suchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5264-2169","authenticated-orcid":false,"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"71307_CR1","doi-asserted-by":"publisher","first-page":"108078","DOI":"10.1016\/j.diabres.2020.108078","volume":"162","author":"A Sinclair","year":"2020","unstructured":"Sinclair, A. et al. Diabetes and global ageing among 65\u201399-year-old adults: findings from the International Diabetes Federation Diabetes Atlas. Diab. Res. Clin. Pract. 162, 108078 (2020).","journal-title":"Diab. Res. Clin. Pract."},{"key":"71307_CR2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee; 13. older adults: standards of care in diabetes\u20142024. Diabetes Care 47, S244-S257 (2023).","DOI":"10.2337\/dc24-S013"},{"key":"71307_CR3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee; 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024. Diabetes Care 47, S158-S178 (2023).","DOI":"10.2337\/dc24-S009"},{"key":"71307_CR4","doi-asserted-by":"publisher","first-page":"e001279","DOI":"10.1136\/bmjdrc-2020-001279","volume":"8","author":"C Engler","year":"2020","unstructured":"Engler, C. et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012\u20132018. BMJ Open Diab. Res. Care 8, e001279 (2020).","journal-title":"BMJ Open Diab. Res. Care"},{"key":"71307_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner, G. et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc. Diabetol. 19, 185 (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"71307_CR6","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2666-7568(23)00039-9","volume":"4","author":"S Bellary","year":"2023","unstructured":"Bellary, S. & Barnett, A. H. SGLT2 inhibitors in older adults: overcoming the age barrier.  Lancet Healthy Longev. 4, e127\u2013e128 (2023).","journal-title":"Lancet Healthy Longev."},{"key":"71307_CR7","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025. Diabetes Care 48, S181-S206 (2024).","DOI":"10.2337\/dc25-S009"},{"key":"71307_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.7326\/M23-2788","volume":"177","author":"A Qaseem","year":"2024","unstructured":"Qaseem, A. et al. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the. Ann. Intern. Med. 177, 658\u2013666 (2024).","journal-title":"Ann. Intern. Med."},{"key":"71307_CR9","doi-asserted-by":"publisher","first-page":"e000651","DOI":"10.1136\/bmjmed-2023-000651","volume":"2","author":"R Khera","year":"2023","unstructured":"Khera, R. et al. Multinational patterns of second-line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Med. 2, e000651 (2023).","journal-title":"BMJ Med."},{"key":"71307_CR10","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","volume":"394","author":"MA Suchard","year":"2019","unstructured":"Suchard, M. A. et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.  Lancet 394, 1816\u20131826 (2019).","journal-title":"Lancet"},{"key":"71307_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/jamia\/ocaa103","volume":"27","author":"MJ Schuemie","year":"2020","unstructured":"Schuemie, M. J. et al. Principles of large-scale evidence generation and evaluation across a network of databases (LEGEND). J. Am. Med. Inform. Assoc. 27, 1331\u20131337 (2020).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"71307_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jacc.2024.05.069","volume":"84","author":"R Khera","year":"2024","unstructured":"Khera, R. et al. Comparative effectiveness of second-line antihyperglycemic agents for cardiovascular outcomes: a multinational, federated analysis of LEGEND-T2DM. J. Am. Coll. Cardiol. 84, 904\u2013917 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"71307_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jamia\/ocu023","volume":"22","author":"EA Voss","year":"2015","unstructured":"Voss, E. A. et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inform. Assoc. 22, 553\u2013564 (2015).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"71307_CR14","unstructured":"Blacketer C. Janssen CDM Documentation. https:\/\/ohdsi.github.io\/ETL-LambdaBuilder\/ (2025)."},{"key":"71307_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/CP203320","volume":"56","author":"W Rathmann","year":"2018","unstructured":"Rathmann, W., Bongaerts, B., Carius, H. J., Kruppert, S. & Kostev, K. Basic characteristics and representativeness of the German Disease Analyzer database. Int J. Clin. Pharm. Ther. 56, 459\u2013466 (2018).","journal-title":"Int J. Clin. Pharm. Ther."},{"key":"71307_CR16","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1093\/ije\/dyac068","volume":"51","author":"M Recalde","year":"2022","unstructured":"Recalde, M. et al. Data resource profile: the information system for research in primary care (SIDIAP). Int. J. Epidemiol. 51, e324\u2013e336 (2022).","journal-title":"Int. J. Epidemiol."},{"key":"71307_CR17","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1056\/NEJMoa2200433","volume":"387","author":"The GRADE Study Research Group","year":"2022","unstructured":"The GRADE Study Research Group Glycemia reduction in type 2 diabetes\u2014glycemic outcomes. N. Engl. J. Med. 387, 1063\u20131074 (2022).","journal-title":"N. Engl. J. Med."},{"key":"71307_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"71307_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644\u2013657 (2017).","journal-title":"N. Engl. J. Med."},{"key":"71307_CR20","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen, B. L. et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145, 1460\u20131470 (2022).","journal-title":"Circulation"},{"key":"71307_CR21","doi-asserted-by":"publisher","first-page":"e078483","DOI":"10.1136\/bmj-2023-078483","volume":"385","author":"EL Fu","year":"2024","unstructured":"Fu, E. L. et al. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population-based cohort study. BMJ 385, e078483 (2024).","journal-title":"BMJ"},{"key":"71307_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamainternmed.2024.3806","volume":"184","author":"T Huang","year":"2024","unstructured":"Huang, T. et al. GLP-1RA vs DPP-4i use and rates of hyperkalemia and RAS blockade discontinuation in type 2 diabetes. JAMA Intern. Med. 184, 1195\u20131203 (2024).","journal-title":"JAMA Intern. Med."},{"key":"71307_CR23","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1210\/jc.2019-00198","volume":"104","author":"D LeRoith","year":"2019","unstructured":"LeRoith, D. et al. Treatment of diabetes in older adults: an endocrine society* clinical practice guideline. J. Clin. Endocrinol. Metab. 104, 1520\u20131574 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"71307_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2337\/dci22-0014","volume":"45","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui, R. et al. Heart failure: an underappreciated complication of diabetes. a consensus report of the American Diabetes Association. Diab. Care 45, 1670\u20131690 (2022).","journal-title":"Diab. Care"},{"key":"71307_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12325-018-0824-8","volume":"36","author":"CM Apovian","year":"2019","unstructured":"Apovian, C. M., Okemah, J. & O\u2019Neil, P. M. Body weight considerations in the management of type 2 diabetes. Adv. Ther. 36, 44\u201358 (2019).","journal-title":"Adv. Ther."},{"key":"71307_CR26","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. I. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation 134, 752\u2013772 (2016).","journal-title":"Circulation"},{"key":"71307_CR27","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer, S. C. et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. Bmj 372, m4573 (2021).","journal-title":"Bmj"},{"key":"71307_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown, E., Heerspink, H. J. L., Cuthbertson, D. J. & Wilding, J. P. H. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.  Lancet 398, 262\u2013276 (2021).","journal-title":"Lancet"},{"key":"71307_CR29","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick, M., Schneeweiss, S. & Patorno, E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N. Engl. J. Med. 376, 2300\u20132302 (2017).","journal-title":"N. Engl. J. Med."},{"key":"71307_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","volume":"173","author":"A Douros","year":"2020","unstructured":"Douros, A. et al. Sodium\u2013glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis. Ann. Intern. Med. 173, 417\u2013425 (2020).","journal-title":"Ann. Intern. Med."},{"key":"71307_CR31","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/dom.14300","volume":"23","author":"M Fralick","year":"2021","unstructured":"Fralick, M., Colacci, M., Thiruchelvam, D., Gomes, T. & Redelmeier, D. A. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a nationwide cohort study of older adults with diabetes mellitus. Diab., Obes. Metab. 23, 950\u2013960 (2021).","journal-title":"Diab., Obes. Metab."},{"key":"71307_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2337\/dc20-1464","volume":"44","author":"E Patorno","year":"2021","unstructured":"Patorno, E. et al. Comparative effectiveness and safety of sodium\u2013glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diab. Care 44, 826\u2013835 (2021).","journal-title":"Diab. Care"},{"key":"71307_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01743-5","volume":"22","author":"A Goldman","year":"2023","unstructured":"Goldman, A. et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (\u2265\u200975 years): a retrospective, pharmacovigilance study. Cardiovasc. Diabetol. 22, 16 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"71307_CR34","doi-asserted-by":"publisher","first-page":"e2130762","DOI":"10.1001\/jamanetworkopen.2021.30762","volume":"4","author":"M Zhuo","year":"2021","unstructured":"Zhuo, M. et al. Association of sodium-glucose cotransporter\u20132 inhibitors with fracture risk in older adults with type 2 diabetes. JAMA Netw. Open 4, e2130762\u2013e2130762 (2021).","journal-title":"JAMA Netw. Open"},{"key":"71307_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct. Target. Ther. 9, 234 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"71307_CR36","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu, L., Chen, J., Wang, L., Chen, C. & Chen, L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front. Endocrinol. 13, 1043789 (2022).","journal-title":"Front. Endocrinol."},{"key":"71307_CR37","doi-asserted-by":"publisher","first-page":"1364110","DOI":"10.3389\/fphar.2024.1364110","volume":"15","author":"KA Alenzi","year":"2024","unstructured":"Alenzi, K. A., Alsuhaibani, D., Batarfi, B. & Alshammari, T. M. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 15, 1364110 (2024).","journal-title":"Front. Pharmacol."},{"key":"71307_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/17512433.2020.1736041","volume":"13","author":"AK Singh","year":"2020","unstructured":"Singh, A. K., Gangopadhyay, K. K. & Singh, R. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Rev. Clin. Pharmacol. 13, 461\u2013468 (2020).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"71307_CR39","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"71307_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.  Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"71307_CR41","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228\u20131239 (2017).","journal-title":"N. Engl. J. Med."},{"key":"71307_CR42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dom.13924","volume":"22","author":"M Abd El Aziz","year":"2020","unstructured":"Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E. & Nauck, M. A. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diab., Obes. Metab. 22, 699\u2013704 (2020).","journal-title":"Diab., Obes. Metab."},{"key":"71307_CR43","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/ehjcvp\/pvaf037","volume":"11","author":"A Kalayci","year":"2025","unstructured":"Kalayci, A. et al. Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis. Eur. Heart J. - Cardiovasc. Pharmacother. 11, 552\u2013561 (2025).","journal-title":"Eur. Heart J. - Cardiovasc. Pharmacother."},{"key":"71307_CR44","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1111\/jgs.70143","volume":"73","author":"K Minami","year":"2025","unstructured":"Minami, K. et al. SGLT2 inhibitors in older adults with cardiovascular disease: a systematic review and meta-analysis. J. Am. Geriatr. Soc. 73, 3708\u20133718 (2025).","journal-title":"J. Am. Geriatr. Soc."},{"key":"71307_CR45","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","volume":"9","author":"SA Lee","year":"2024","unstructured":"Lee, S. A. & Riella, L. V. Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers. Kidney Int. Rep. 9, 1601\u20131613 (2024).","journal-title":"Kidney Int. Rep."},{"key":"71307_CR46","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Care in Diabetes\u20142025. Diabetes Care 48, S266-S282 (2024).","DOI":"10.2337\/dc25-S013"},{"key":"71307_CR47","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies, M. J. et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65, 1925\u20131966 (2022).","journal-title":"Diabetologia"},{"key":"71307_CR48","unstructured":"Hripcsak G., et al. RESEARCH PROTOCOL Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus. https:\/\/ohdsi-studies.github.io\/LegendT2dm\/Protocol.html (2021)."},{"key":"71307_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057977","volume":"12","author":"R Khera","year":"2022","unstructured":"Khera, R. et al. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open 12, e057977 (2022).","journal-title":"BMJ Open"},{"key":"71307_CR50","doi-asserted-by":"crossref","unstructured":"Hripcsak G. et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. In: MEDINFO 2015: eHealth-enabled Health). IOS Press (2015).","DOI":"10.3233\/978-1-61499-564-7-574"},{"key":"71307_CR51","first-page":"966","volume":"310","author":"M Schuemie","year":"2024","unstructured":"Schuemie, M. et al. Health-Analytics Data To Evidence Suite (Hades): open-source software for observational research. Stud. Health Technol. Inf. 310, 966\u2013970 (2024).","journal-title":"Stud. Health Technol. Inf."},{"key":"71307_CR52","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.  Lancet 370, 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"71307_CR53","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2337\/dc18-su09","volume":"41","author":"AA Diabetes","year":"2018","unstructured":"Diabetes, A. A. Updates to the standards of medical care in diabetes\u20142018. Diab. Care 41, 2045\u20132047 (2018).","journal-title":"Diab. Care"},{"key":"71307_CR54","unstructured":"Rao G. PhenotypeLibrary: the OHDSI phenotype library. https:\/\/ohdsi.github.io\/PhenotypeLibrary\/ (2024)."},{"key":"71307_CR55","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/ije\/dyy120","volume":"47","author":"Y Tian","year":"2018","unstructured":"Tian, Y., Schuemie, M. J. & Suchard, M. A. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int. J. Epidemiol. 47, 2005\u20132014 (2018).","journal-title":"Int. J. Epidemiol."},{"key":"71307_CR56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/sim.5925","volume":"33","author":"MJ Schuemie","year":"2014","unstructured":"Schuemie, M. J., Ryan, P. B., DuMouchel, W., Suchard, M. A. & Madigan, D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat. Med. 33, 209\u2013218 (2014).","journal-title":"Stat. Med."},{"key":"71307_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/CER.S40357","volume":"3","author":"AM Walker","year":"2013","unstructured":"Walker, A. M. et al. A tool for assessing the feasibility of comparative effectiveness research. Comp. Effect. Res. 3, 11\u201320 (2013).","journal-title":"Comp. Effect. Res."},{"key":"71307_CR58","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/aje\/126.2.356","volume":"126","author":"B Armstrong","year":"1987","unstructured":"Armstrong, B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am. J. Epidemiol. 126, 356\u2013358 (1987).","journal-title":"Am. J. Epidemiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71307-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:02:22Z","timestamp":1784854942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71307-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71307"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71307-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Sawano has received partial research funding through Yale University from PolyBio, Pfizer, and Norvatis. He has also received lecture honoraria from Boehringer Ingelheim and Abbott and receives compensation for his role as Execute Associate Editor for JACC, all outside the scope of this work. Dr. Nishimura received support from the National Institute of General Medical Sciences of the National Institute of Health. Dr. Khera is an associate editor at JAMA; and has received support from the National Institutes of Health (awards R01 AG089981, R01 HL167858 and K23 HL153775) and the Doris Duke Charitable Foundation (award 2022060); has received research support, through Yale University, from Bristol Myers Squibb, Novo Nordisk, and BridgeBio; is a coinventor of U.S. provisional patent applications WO2023230345A1, US20220336048A1, 63\/177,117, 63\/346,610, 63\/428,569, 63\/484,426, 63\/508,315, 63\/580,137, 63\/606,203, 63\/619,241, and 63\/562,335, unrelated to the present work; and is a cofounder of Evidence2Health and Ensight-AI, precision health platforms to improve evidence-based cardiovascular care and cardiovascular diagnostics. Dr. Thangaraj is a coinventor on provisional patent 63\/606,203, unrelated to the present work, and is funded by grant 5T32 HL155000-03. Ms. Blacketer, Dr. Ostropolets, Dr. Schuemie, and Dr. Ryan are employees of Johnson & Johnson and shareholders of Johnson & Johnson. Ms. Li and Ms. Yin are employees of IQVIA. Ms. Zandt is an employee of IQVIA and a shareholder of IQVIA. Dr. Lau received research funding from Diabetes UK outside the scope of this work. Dr. Minty discloses a consulting relationship with Orpyx Medical Technologies, equity ownership in Orpyx Medical Technologies, and status as co-inventor on 2 patent applications (US 20250000440, US 20250000440), all of which are outside the scope of this work. Dr. You reports being a chief executive officer of PHI Digital Healthcare and grants from Daiichi Sankyo. He is a co-inventor of granted Korea Patent DP-2023-1223 and DP-2023-0920, and pending Patent Applications DP-2024-0909, DP-2024-0908, DP-2022-1658, DP-2022-1478, and DP-2022-1365, unrelated to current work. Dr. Man has received support from the C.W. Maplethorpe Fellowship, the National Institute of Health Research, European Commission Framework Horizon 2020, the Hong Kong Research Grant Council, and the Innovation and Technology Commission of the Hong Kong Special Administration Region Government, outside the submitted work). Dr. Hripcsak received a grant from Johnson & Johnson for methods work unrelated to this study. Dr. Krumholz has received expenses and\/or personal fees from UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract\/4Catalyst, F-Prime, the Siegfried and Jensen Law Firm, the Arnold and Porter Law Firm, and the Martin\/Baughman Law Firm; is a cofounder of Refactor Health, HugoHealth, and Ensight-AI; and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare and Medicaid Services and, through Yale University, from Johnson & Johnson. Dr. Suchard receives additional contracts and grants from the US Food & Drug Administration, the US National Institutes of Health, Janssen Research & Development and Gliead Sciences outside the scope of this work. Dr. Lu received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under awards R01HL69954 and R01HL169171), the Patient-Centered Outcomes Research Institute (under award HM-2022C2-28354), Sentara Research Foundation, and Novartis through Yale University. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7195"}}